Research ended
KalVista Pharmaceuticals, Inc. (KALV) was acquired by Chiesi for $27.00 a share in cash on 12 June 2026.
Our research on KalVista Pharmaceuticals, Inc. ended on . Once a takeover closes, the shares stop trading under KALV and there is nothing left to research. The last note, from , is below.
We keep this page so links to it still work and what we published about the stock stays on the record.
The last thesis
KalVista Pharmaceuticals has no tradable equity thesis: Chiesi Group completed its $27.00-per-share cash acquisition on 11 June 2026 and the common shares were cancelled. Only documented restoration of the common stock would reopen an equity case.